De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
2021/04/05 by Koji Sasaki, Farhad Ravandi, Tapan M. Kadia +5 · 27 citations
Medicine · #Acute Myeloid Leukemia Research #Acute Lymphoblastic Leukemia research #Neutropenia and Cancer Infections
paper · pdf · doi:10.1002/cncr.33458
Abstract
BACKGROUND: Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML). METHODS: The authors identified 29,107 patients who were diagnosed with de novo AML between 1980 and 2017 in the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Patients were categorized into 5 age groups (ages birth to 14, 15-39, 40-59, 60-69, and ≥70 years) and 4 calendar periods (1980-1989, 1990-1999, 2000-2009, and 2010-2017). The outcomes of patients who had AML within these categories were analyzed. RESULTS: The overall 5-year survival rates in patients with AML were 9%, 15%, 22%, and 28% in the decades 1980 to 1989, 1990 to 1999, 2000 to 2009, and 2010 to 2017, respectively. Among patients aged 15 to 39 years, the 5-year survival rates were 24%, 41%, 52%, and 63%, respectively; among those aged ≥70 years, the 5-year survival rates were 1%, 2%, 3%, and 5%, respectively. Four-week mortality was surprising high among adults and older patients (range, 20%-45%), even in modern times. Overall, survival continued to improve over the calendar periods and was best in the period from 2010 to 2017. Survival improvement was noticeable across all age groups except patients aged ≥70 years, in whom the estimated 5-year survival rate remained 5% even during the period from 2010 to 2017. CONCLUSIONS: The outcomes of patients with AML showed incremental improvement over time in a population-based study of the Surveillance, Epidemiology, and End Results data. The introduction since 2017 of targeted therapies among older patients and optimizations in supportive care hopefully will continue to improve outcomes in AML, particularly among older patients.
Citations
Cited by
- Genotype-immunophenotype relationships in NPM1 -mutant AML clonal evolution uncovered by single cell multiomic analysis
- Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis
- Acute myeloid leukemia: current progress and future directions. [europepmc]
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. [europepmc]
- Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. [europepmc]
- Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. [europepmc]
- The cure of leukemia through the optimist's prism. [europepmc]
- Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. [europepmc]
- Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. [europepmc]
- Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study. [europepmc]
- Prediction of survival with intensive chemotherapy in acute myeloid leukemia. [europepmc]
- A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. [europepmc]
- New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. [europepmc]
- Current Understanding of DDX41 Mutations in Myeloid Neoplasms. [europepmc]
- Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors. [europepmc]
- Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. [europepmc]
- Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. [europepmc]
- Novel Therapeutic Targets in Acute Myeloid Leukemia (AML). [europepmc]
- Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019. [europepmc]
- Identification of hub genes and potential molecular mechanisms related to drug sensitivity in acute myeloid leukemia based on machine learning. [europepmc]
- Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia. [europepmc]
- GNL3L exhibits pro-tumor activities via NF-κB pathway as a poor prognostic factor in acute myeloid leukemia. [europepmc]
- Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. [europepmc]
- Current status and research directions in acute myeloid leukemia. [europepmc]
- Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. [europepmc]
- Acute myeloid leukemia management and research in 2025. [europepmc]
- Global assessment of leukemia care quality: insights from the quality of care index (QCI) from 1990 to 2021. [europepmc]
Related